National Institute of Mental Health (NIMH)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Mental Health (NIMH) sits in the top decile of US sponsors by registered trial count (#103 of 15,742 sponsors by registered trial count).
National Institute of Mental Health (NIMH): 343 sponsored US clinical trials, 42 recruiting.
National Institute of Mental Health (NIMH) sponsors 343 registered US clinical trials on ClinicalTrials.gov, 42 of them currently recruiting, and 256 completed. 29 of these trials are in Phase 3-4 (later-stage) and 106 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 21 trials.
Top-decile sponsor footprint
National Institute of Mental Health (NIMH) ranks in the top decile of sponsors by registered trial count (#103 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
256 of 296 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
343 total, page 4 of 7
PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28
NCT00407693
Minocycline to Treat Childhood Regressive Autism
NCT00409747
PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00397748
Protein Synthesis in the Brain of Patients With Fragile X Syndrome
NCT00362843
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients
NCT00369798
The Antidepressant Efficacy of the Anticholinergic Scopolamine
NCT00369915
Identifying the Role of Oxytocin and Vasopressin in the Functioning of Neurocognitive Systems Involved in Mood Disorders
NCT00325065
Clinical and Immunological Investigations of Subtypes of Autism
NCT00298246
PET Imaging of Brain Peripheral Benzodiazepine Receptors
NCT00283920
PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY
NCT00263523
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram
NCT00250172
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
NCT00128401
Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders
NCT00251303
Dopamine Receptor Imaging in Mood Disorders
NCT00116077
Attention and Visual Perception
NCT00111293
Org 24448 to Treat Major Depression
NCT00113022
The Role of Norepinephrine in Emotional Processing
NCT00109642
Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study
NCT00105274
Effect of Transcranial Magnetic Stimulation on Memory
NCT00105118
Brain Changes in Children and Adolescents With Behavioral Problems
NCT00104039
Neurobiological Mechanisms in Panic Disorder
NCT00103987
Role of Substance P in Post-Traumatic Stress Disorder
NCT00102102
Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication
NCT00375843
Hormonal Causes of Menstrual-Related Mood Disorders
NCT00100360
Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders
NCT00097175
Relationship of Dopamine to Cognitive Function in Parkinson's Disease
NCT00094601
Effect of Gabapentin on GABA Concentration and Emotional Processing
NCT00094510
Investigating the Role of Serotonin in Emotional Processing Through the Use of Tryptophan Depletion
NCT00090831
Psychological Mechanisms of Behavioral Dysregulation
NCT00352456
Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ
NCT00088738
Rapid Antidepressant Effects of Ketamine in Major Depression
NCT00088699
Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112
NCT00088517
Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives
NCT00089414
Lexapro and Pramipexole and to Treat Major Depression
NCT00086307
Serotonin Transporters in Alcoholism
NCT00085865
Family Study of Affective and Anxiety Spectrum Disorders
NCT00071786
Genetic Causes of Panic Disorder
NCT00083265
Serotonin Transporters in Obsessive-Compulsive-Related Disorders
NCT00082550
Use of [18F]FECNT in Positron Emission Tomography
NCT00083629
Function of Catecholamines in the Brain During Depression
NCT00082030
Dutasteride to Treat Women With Menstrually Related Mood Disorders
NCT00082043
Neurocardiac Control in Major Depression
NCT00084162
Rapid Antidepressant Effects of Yohimbine in Major Depression
NCT00078715
FMRI Study of Performance During a Probabilistic Reversal Learning Task in Depression
NCT00075296
The Psychobiology of Childhood Temperament
NCT00060775
Evaluating Brain Responses to Facial Expressions in Major Depressive Disorder
NCT00071123
Psychobiological Mechanisms of Resilience to Trauma
NCT00069212
Propranolol for the Treatment of Acute Stress Disorder
NCT00069355
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
NCT00070694
Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder
NCT00069225
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 61 |
| Phase 2 | 45 |
| Phase 3 | 8 |
| Phase 4 | 21 |
Therapeutic Areas
What is open in the National Institute of Mental Health (NIMH) pipeline
42 recruiting of 343 indexed (12% open); 256 completed (75%).
Phase mix: 29 late (III/IV) vs 106 early (I/II) (early-phase heavy).
Top condition: Healthy (21 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Mental Health (NIMH): open-pipeline peers nationwide
Peers matched on 343 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
National Institute of Mental Health (NIMH) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 343 trials (± recruiting share)
- Children's Oncology Group · 342 trials · 10% recruiting
- Montefiore Medical Center · 345 trials · 19% recruiting
- Ohio State University Comprehensive Cancer Center · 341 trials · 23% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Augusta University · 12% recruiting · 106 trials
- University of Iowa · 12% recruiting · 228 trials
- Daiichi Sankyo · 12% recruiting · 236 trials
- Friends Research Institute · 12% recruiting · 41 trials
Related
What to do with this National Institute of Mental Health (NIMH) page
343 registered trials is a research-attention snapshot, not an endorsement of National Institute of Mental Health (NIMH) or any single study.
- 42 of National Institute of Mental Health (NIMH)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition National Institute of Mental Health (NIMH) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute of Mental Health (NIMH) pipeline card: 343 registered trials from official public datasets.Report a data error.